No Data Yet
The global blood glucose monitor market is projected to expand to $25.4 billion by 2030, growing at a 9.1% compound annual growth rate, driven by a rising diabetes prevalence and technological advancements.
A new analysis identifies several U.S. stocks, such as Beacon Financial trading at a 44.8% discount, as undervalued based on cash flows despite a broader market decline in December 2025.
Jim Cramer voiced concerns over DexCom's (DXCM) high stock valuation, citing potential long-term market disruption from the growing class of GLP-1 drugs used for weight loss and diabetes management, creating uncertainty for the medical device maker.
U.S. healthcare and pharmaceutical stocks are facing a period of heightened volatility driven by the obesity drug arms race, shifting U.S. policy on healthcare subsidies, and an increasingly dual-natured FDA that is both accelerating approvals and intensifying safety scrutinies. These factors create a complex investment landscape heading into the week of December 15, 2025.